DE69825440D1 - VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN - Google Patents

VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN

Info

Publication number
DE69825440D1
DE69825440D1 DE69825440T DE69825440T DE69825440D1 DE 69825440 D1 DE69825440 D1 DE 69825440D1 DE 69825440 T DE69825440 T DE 69825440T DE 69825440 T DE69825440 T DE 69825440T DE 69825440 D1 DE69825440 D1 DE 69825440D1
Authority
DE
Germany
Prior art keywords
treatment
leukämien
taurolidine
drug
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825440T
Other languages
English (en)
Other versions
DE69825440T2 (de
Inventor
H Morrissey
Anne Hamik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of DE69825440D1 publication Critical patent/DE69825440D1/de
Application granted granted Critical
Publication of DE69825440T2 publication Critical patent/DE69825440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69825440T 1997-05-22 1998-05-22 VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN Expired - Fee Related DE69825440T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4764297P 1997-05-22 1997-05-22
US47642P 1997-05-22
PCT/US1998/010494 WO1998052572A1 (en) 1997-05-22 1998-05-22 Use of taurolidine for treatment of leukemias

Publications (2)

Publication Number Publication Date
DE69825440D1 true DE69825440D1 (de) 2004-09-09
DE69825440T2 DE69825440T2 (de) 2005-07-28

Family

ID=21950114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825440T Expired - Fee Related DE69825440T2 (de) 1997-05-22 1998-05-22 VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN

Country Status (7)

Country Link
US (1) US6303596B1 (de)
EP (1) EP0983069B1 (de)
AT (1) ATE272404T1 (de)
AU (1) AU734460B2 (de)
CA (1) CA2290537C (de)
DE (1) DE69825440T2 (de)
WO (1) WO1998052572A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
KR100565883B1 (ko) 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 응고 및 종양 치료용 조직 인자 방법 및 조성물
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US6429224B1 (en) * 1999-12-06 2002-08-06 Rhode Island Hospital, A Lifespan Partner Use of taurolidine to treat tumors
EP1797884B1 (de) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidin oder Taurultam zur Verwendung bei der Behandlung von Tumoren der Prostata, des Kolons, der Lungen und von wiederkehrendem Glioblastoma multiforme.
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
CA2462564C (en) 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
JP5043294B2 (ja) 2003-09-29 2012-10-10 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 中皮腫を治療する方法
WO2005115357A2 (en) * 2004-05-14 2005-12-08 Hans-Dietrich Polaschegg Taurolidine formulations and delivery
EP2061429A2 (de) * 2006-09-07 2009-05-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Verfahren zur behandlung von knochenkrebs
CN111635888A (zh) * 2020-04-21 2020-09-08 西南医科大学附属医院 双黄连用于诱导人急性t淋巴细胞白血病细胞凋亡的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions

Also Published As

Publication number Publication date
WO1998052572A1 (en) 1998-11-26
AU734460B2 (en) 2001-06-14
CA2290537C (en) 2007-10-02
CA2290537A1 (en) 1998-11-26
DE69825440T2 (de) 2005-07-28
US6303596B1 (en) 2001-10-16
AU7590698A (en) 1998-12-11
ATE272404T1 (de) 2004-08-15
EP0983069A1 (de) 2000-03-08
EP0983069B1 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE60139466D1 (de) Behandlung von diabetes
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69620786D1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
ATE237328T1 (de) Verwendung von aryl(oder heteroaryl)- azolylcarbinolderivaten in der herstellung von medikamenten zur behandlung von neurogenen entzündungen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee